Overview

A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia

Status:
Completed

Trial end date:
2008-11-01

Target enrollment:

Participant gender:

Summary

In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with azacitidine to patients with high-risk myelodysplastic syndromes or acute myelogenous leukemia.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Mirati Therapeutics Inc.

Treatments:

Azacitidine
Mocetinostat